kashi-health-logo

Kashi Clinical Laboratories
10101 SW Barbur Blvd, Suite 200
Portland, OR 97219

1 877 879-1815
1000 characters left

Contact Information

Other Information

Practice Information

Thank you for your interest in Kashi Health's genetic testing services.

Our genetic tests require guidance from a licensed healthcare provider. You may find a qualified provider from our list of approved professionals in the link below, or you may email your provider directly requesting that they contact us to request a genetic test. We wish you the best in your pursuit of healthy living.

1-877-879-1815

Sjögren's Syndrome

Sjögren's syndrome is a late onset chronic autoimmune disease which affects the exocrine glands, mainly the salivary and lacrimal glands, resulting in insufficient secretion by those glands.

It is characterized by a progressive lymphoid and plasma cell infiltration of the salivary and tear glands, accompanied by the production of autoantibodies leading to mucosal (dry mouth) and conjunctival (dry eyes) dryness. Sjögren's may occur alone (primary Sjögren's) or secondary to other autoimmune disorders such as systemic lupus erythematosus (SLE) and rheumatoid arthritis. Primary Sjögren's generally affects females (9/10 patients are female) and has an onset at around age 40. The reasons for the gender bias are unknown though hormones such as prolactin have been implicated.

Clinical Utility:

Multiple genetic loci have been shown to contribute to the risk of developing Sjögren's. Of these, the HLA class II DR and DQ are the most important. HLA-DQA1*05, DQB1*02, and DRB1*03 alleles are the risk factors for disease. Sjögren's is diagnosed on the basis of screening questions, eye tests and salivary flow rate tests rather than on genetic testing. Genetic testing in Sjögren's may be of value in providing insights into the mechanism of the disease, thereby potentially suggesting strategies for prevention and treatment.

Method:

Kashi Clinical Laboratories utilizes a combination of PCR-SSO (polymerase chain reaction sequence specific oligonucleotide typing) and SBT (sequence based typing) for testing.

Kashi's in-house laboratory and experienced health professionals ensure that customer service is personal, timely, and tailored to every patient's needs.

What is the Next Step? 

Make Kashi Health's Genetic Testing part of your patient's treatment plan today. 

Questions? Please contact our customer service team at 877-879-1815 or 503-206-4989 or by email at This email address is being protected from spambots. You need JavaScript enabled to view it. . We are available Monday through Friday, from 8:00 AM - 5:00 PM, Pacific Time.

 References
  1. Arnett FC. Histocompatibility typing in the rheumatic diseases. Diagnostic and prognostic implications. Rheum Dis Clin North Am. 1994; 20:371.
  2. Cruz-Tapias P et al. HLA and Sjögren's syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev. 2012 Feb;11(4):281-7.
  3. Bolstad AI et al. HLA markers and clinical characteristics in Caucasians with primary Sjögren's syndrome. J Rheumatol. 2001; 28:1554.
  4. Kang HI et al. Comparison of HLA class II genes in Caucasoid, Chinese, and Japanese patients with primary Sjögren's syndrome. J Immunol. 1993; 150:3615.
  5. Mattey DL et al. Association between HLA-DRB1*15 and secondary Sjögren's syndrome in patients with rheumatoid arthritis. J Rheumatol. 2000; 27:2611.
  6. Takahashi M et al. HLA and CTLA4 polymorphisms may confer a synergistic risk in the susceptibility to Graves' disease. J Hum Genet. 2010; 55:323.
  7. El Miedany YM. Hyperprolactinemia in Sjogren's syndrome: a patient subset or a disease manifestation? Joint Bone Spine. 2004 May; 71(3):203-8.